Lyell
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
201 Haskins Way, South San Francisco, Ca...Phone Number
(650) 695-0677Website
www.lyell.comRevenue
<$5 MillionStock Symbol
LYELIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Lyell
Lyell Immunopharma, Inc., operating as Lyell, is a clinical-stage biotechnology company dedicated to developing next-generation cell therapies for patients with cancer. The organization specializes in advancing innovative chimeric antigen receptor T-cell therapies and related cellular immunotherapies designed to improve treatment outcomes for individuals with hematologic malignancies and solid tumors. The company's scientific mission centers on overcoming the biological limitations that reduce the effectiveness and durability of conventional cell therapies, thereby expanding the potential of engineered immune cells to provide long-lasting clinical benefit for patients with difficult-to-treat cancers.Explore more
Lyell Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lyell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Lyell launches new products
Check if Lyell has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Lyell has new funding data
Check out if Lyell is spiking on competitors!
Earning: See what the market has to say on Lyell recently announced quarterly report
Click to see if Lyell had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Lyell
Lyell, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Lyell
Compare insights from companies similar to Lyell, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lyell is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lyell is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lyell.
Lyell financials insights
Gather financial insights about Lyell, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$100M
Lyell Tech Stack
A closer look at the technologies used by Lyell
Most Recent Scoops
Person-Based
Open Position
Person-Based
Share Placement, Finance
Person-Based
Hiring Plans
Hiring Plans
Lyell News & Media
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026, at 1:30 pm Eastern Time.Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
SOUTH SAN FRANCISCO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, is announcing today new safety data from the ongoing Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third- and later-line (3L+) sLyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today provided an update on the safety profile of LYL273 in its ongoing U.S. Phase 1 clinical trial in patients with relapsed or refractory metastatic colorectal cancer (mCRC), and announced the Phase 1 trial has been amended to enable seamless expansLyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
SOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that the Company will present data from its ongoing Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel) in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) at the European Hematology Association (EH
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lyell
Sign Up For FreeTo access detailed company insights
Lyell Immunopharma, Inc., operating as Lyell, is a clinical-stage biotechnology company dedicated to developing next-generation cell therapies for patients with cancer. The organization specializes in advancing innovative chimeric antigen receptor T-cell therapies and related cellular immunotherapies designed to improve treatment outcomes for indiv... Read More
